Insight Companies

Autoimmune Hepatitis Diagnosis and Treatment Market Outlook (2024 – 2032)

Market Insights: Growth in Autoimmune Hepatitis Diagnosis and Treatment

The market for autoimmune hepatitis diagnosis and treatment is projected to expand significantly, increasing from an estimated USD 14.03 billion in 2023 to over USD 19.15 billion by 2032. This growth reflects a steady compound annual growth rate (CAGR) of 3.3% during the forecast period, driven by rising demand for innovative treatment solutions and improved access to healthcare services globally.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5124

Recent Developments

  • In January 2022, the U.S. Food and Drug Administration (FDA) granted approval to Lupin’s Tenofovir alafenamide tablets for the treatment of chronic hepatitis B viral infection, offering a new treatment option for patients battling this condition.
  • In June 2022, Echosens partnered with Novo Nordisk to improve accessibility to non-invasive tests for diagnosing Non-Alcoholic Steatohepatitis (NASH), a liver condition. Their collaboration aims to expand NASH diagnoses, particularly for those with severe cases, and increase the number of diagnoses by four times by 2025.

Key Companies in the Autoimmune Hepatitis Diagnosis and Treatment Market

Abbott

Abbott is a global healthcare company that develops and manufactures a broad range of diagnostic tools, medical devices, and pharmaceutical products. Abbott offers diagnostic solutions for various liver conditions, including autoimmune hepatitis, and is known for its innovative approach to improving healthcare outcomes through accessible and accurate diagnostic tools.

Siemens Healthcare Private Limited

Siemens Healthcare, a division of Siemens AG, specializes in medical technology and healthcare solutions. The company develops imaging systems, diagnostic tests, and healthcare IT solutions. Siemens is a leader in diagnostics, including liver disease-related testing, and aims to improve the accuracy and efficiency of disease detection.

Beckman Coulter

Beckman Coulter, part of Danaher Corporation, is a global leader in providing laboratory instruments and reagents for various diagnostics, including autoimmune hepatitis. Their diagnostic platforms are widely used in healthcare facilities for testing and monitoring liver function, contributing to early disease detection and treatment planning.

Roche Diagnostics

Roche Diagnostics is a major player in the healthcare and diagnostics sector, offering a range of products for disease detection and management. The company is known for developing cutting-edge diagnostic tools, including tests for autoimmune hepatitis, and is committed to advancing healthcare through innovative diagnostic technologies.

Pfizer Inc.

Pfizer is one of the world’s largest pharmaceutical companies, involved in the development of drugs and vaccines for various diseases, including liver diseases. Pfizer has contributed to the autoimmune hepatitis treatment market with its portfolio of antiviral therapies and other liver disease treatments, focusing on advancing patient care through effective and targeted therapies.

GE Healthcare

GE Healthcare is a global leader in medical imaging and diagnostics, offering advanced imaging equipment and diagnostic tools used in the detection and management of liver conditions such as autoimmune hepatitis. GE Healthcare’s technologies play a vital role in improving diagnosis and treatment plans for patients with liver diseases.

Philips Healthcare

Philips Healthcare is a leading innovator in medical imaging and diagnostic technologies. The company focuses on providing non-invasive diagnostic tools for liver diseases, including autoimmune hepatitis. Philips’ solutions enhance the accuracy of disease detection and help in the management of chronic liver conditions through advanced imaging and monitoring systems.

Cadila Pharmaceuticals

Cadila Pharmaceuticals, also known as Zydus Cadila, is an Indian multinational pharmaceutical company that offers a wide range of medicines, including those for liver diseases. The company is engaged in the development of both diagnostic and therapeutic solutions for autoimmune hepatitis, with an emphasis on improving patient care and treatment options in emerging markets.

Bristol Myers Squibb Company

Bristol Myers Squibb (BMS) is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies, including those for autoimmune diseases. BMS is known for its immunotherapy treatments and plays a significant role in autoimmune hepatitis management through novel drug therapies aimed at modulating the immune response.

Merck & Co., Inc.

Merck & Co., Inc. is a leading global pharmaceutical company involved in the research and development of drugs for various diseases, including autoimmune hepatitis. Merck’s focus on immunology and liver diseases has led to the development of therapies aimed at managing autoimmune hepatitis and preventing disease progression.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/autoimmune-hepatitis-diagnosis-and-treatment-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5124

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Elena Morales

Elena Morales is a healthcare industry expert working at Healthcare Web Wire Consulting Firm, a subsidiary of Towards Healthcare. With her excellent knowledge of the field, Elena helps clients optimize their operations and navigate healthcare regulations. She's dedicated to staying updated on industry trends to make a positive impact on patient care. Elena is known for her professionalism and commitment to excellence, making her a valuable asset to any team.

Recent Posts

Kedrion Biopharma’s COAGADEX® Receives FDA Orphan Drug Designation for Acquired Factor X Deficiency (AFXD)

Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More

1 day ago

Benecard PBF and DecisionRX Join Forces to Personalize and Optimize Pharmacy Benefits

enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More

1 day ago

Four Resilient Biotech Companies Making Waves in a Challenging Market

In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More

1 day ago

Natera Launches TEODOR Trial in Partnership with ABCSG to Advance Personalized Breast Cancer Treatment

cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More

1 day ago

Interventional Radiology Market: Size, Growth, and Leading Companies Driving Innovation

The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More

2 days ago

Physical Therapy Market Growth and Leading Companies Driving Innovation

The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More

2 days ago